CVKD NASDAQ
Cadrenal Therapeutics, Inc. Common Stock
1W: -16.1%
1M: -27.5%
3M: -71.3%
YTD: -86.8%
1Y: -93.1%
3Y: -90.4%
$0.94
-0.03 (-3.07%)
Weekly Expected Move ±13.1%
$1
$1
$1
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$3.4M
52W Range0.8601-14.64
Volume149,584
Avg Volume328,795
Beta1.84
Dividend—
Analyst Ratings
Company Info
CEOQuang X. Pham
Employees5
SectorHealthcare
IndustryBiotechnology
IPO Date2023-01-20
Websitecadrenal.com
822 A1A North
Ponte Vedra, FL 32082
US
Ponte Vedra, FL 32082
US
904 300 0701
About Cadrenal Therapeutics, Inc. Common Stock
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation. Established in 2022, the firm is headquartered in Ponte Vedra, Florida.
Latest News
Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia
Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process
Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation
Cadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 Congress
Cadrenal Therapeutics reports Q1 results
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Pham Quang X | S-Sale | 7,400 | $3.03 | 2026-06-29 |
| Pham Quang X | S-Sale | 9,029 | $3.05 | 2026-06-26 |
| Pham Quang X | S-Sale | 2,127 | $3.00 | 2026-06-25 |
| Pham Quang X | S-Sale | 2,277 | $3.20 | 2026-06-23 |
| Pham Quang X | S-Sale | 9,167 | $3.55 | 2026-06-22 |